BFRG BullFrog AI Holdings, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1829247 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY4.1%
TTM EPS YoY40.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-184.0%
ROA-152.0%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets12.4%
Debt / equity0.00x
Current ratio7.75x
Interest coverage-1,202.80x
Cash quality & payout
Operating cash flow / net income0.97x
Accruals ratio-4.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $116,670 | — | $65,000 | $10,000 | — |
| Cost of revenue | $94,778 | — | $5,200 | $800 | — |
| Gross profit | $21,892 | — | $59,800 | $9,200 | — |
| R&D expense | $1.80M | $2.22M | $1.43M | $609,270 | $25,000 |
| SG&A expense | $4.82M | $5.01M | $3.99M | $1.86M | $327,329 |
| Operating income | -$6.59M | -$7.24M | -$5.37M | -$2.46M | -$555,362 |
| Interest expense | $5,629 | $18,158 | $79,089 | $347,145 | $40,395 |
| Net income | -$6.50M | -$6.99M | -$5.36M | -$2.80M | -$585,840 |
| EBITDA | -$6.59M | -$7.23M | -$5.37M | -$2.45M | — |
| EPS (basic) | -0.63 | -0.85 | -0.89 | -0.70 | -14.00 |
| EPS (diluted) | -0.63 | -0.85 | -0.89 | -0.70 | — |
| Weighted avg. shares (diluted) | 10.34M | 8.25M | 6.05M | 4.01M | — |
| Balance sheet | |||||
| Cash & equivalents | $2.18M | $5.44M | $2.62M | $57,670 | $10,014 |
| Receivables | $0 | — | — | — | — |
| Current assets | $2.58M | $5.55M | $2.77M | $72,670 | $10,014 |
| PP&E, net | $2,525 | $4,250 | $5,974 | $7,699 | — |
| Total assets | $2.81M | $5.55M | $2.78M | $80,369 | $10,014 |
| Current liabilities | $672,022 | $588,090 | $184,350 | $3.14M | $1.02M |
| Short-term debt | — | — | — | — | $49,000 |
| Total liabilities | $672,022 | $588,090 | $184,350 | $3.14M | $1.02M |
| Shareholders' equity | $2.14M | $4.96M | $2.59M | -$3.06M | -$1.01M |
| Shares outstanding | 11.42M | 9.11M | 6.09M | 4.02M | 4.62M |
| Cash flow statement | |||||
| Operating cash flow | -$5.52M | -$5.61M | -$6.00M | -$910,890 | -$382,405 |
| Capital expenditure | — | — | — | $8,744 | — |
| Free cash flow | — | — | — | -$919,634 | — |
| Investing cash flow | — | — | — | -$8,744 | — |
| Financing cash flow | $2.37M | $8.42M | $8.57M | $967,290 | $387,400 |
| Depreciation & amortization | $1,725 | $1,724 | $1,725 | $1,045 | — |
| Stock-based compensation | $1.01M | $943,649 | $631,533 | $340,152 | $98,951 |
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.